Over the past three years, Biogen (NASDAQ: BIIB) stock has taken investors on the ride of a lifetime. Shares have consistently oscillated between over $360 a share to near $200 levels.
As it turns out, investors are heavily betting on the potential for its Alzheimer's disease therapy, aducanumab, to reach commercialization. Can Biogen successfully roll out a treatment to better help patients in a market estimated to reach nearly $5.7 billion by 2027?
Image source: Getty Images.
Source Fool.com